These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 28332364)

  • 21. Pifithrin-μ is efficacious against non-small cell lung cancer via inhibition of heat shock protein 70.
    Zhou Y; Ma J; Zhang J; He L; Gong J; Long C
    Oncol Rep; 2017 Jan; 37(1):313-322. PubMed ID: 28004121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel inhibitor of c-Met and VEGF receptor tyrosine kinases with a broad spectrum of in vivo antitumor activities.
    Awazu Y; Nakamura K; Mizutani A; Kakoi Y; Iwata H; Yamasaki S; Miyamoto N; Imamura S; Miki H; Hori A
    Mol Cancer Ther; 2013 Jun; 12(6):913-24. PubMed ID: 23548264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The oleocanthal-based homovanillyl sinapate as a novel c-Met inhibitor.
    Mohyeldin MM; Akl MR; Ebrahim HY; Dragoi AM; Dykes S; Cardelli JA; El Sayed KA
    Oncotarget; 2016 May; 7(22):32247-73. PubMed ID: 27086914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents.
    Robinson KW; Sandler AB
    Oncologist; 2013; 18(2):115-22. PubMed ID: 23345546
    [TBL] [Abstract][Full Text] [Related]  

  • 25. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
    Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
    Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MACC‑1 antibody target therapy suppresses growth and migration of non‑small cell lung cancer.
    Shi W; Song J; Wang W; Zhang Y; Zheng S
    Mol Med Rep; 2017 Nov; 16(5):7329-7336. PubMed ID: 28944826
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proteasome Inhibitors Diminish c-Met Expression and Induce Cell Death in Non-Small Cell Lung Cancer Cells.
    Li Y; Dong S; Tamaskar A; Wang H; Zhao J; Ma H; Zhao Y
    Oncol Res; 2020 Dec; 28(5):497-507. PubMed ID: 32580819
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Research progress of HGF/MET signaling pathway in EGFR-TKI resistance 
in non-small cell lung cancer].
    Song S; Bi M
    Zhongguo Fei Ai Za Zhi; 2014 Oct; 17(10):755-9. PubMed ID: 25342043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of the met receptor in mesothelioma.
    Mukohara T; Civiello G; Davis IJ; Taffaro ML; Christensen J; Fisher DE; Johnson BE; Jänne PA
    Clin Cancer Res; 2005 Nov; 11(22):8122-30. PubMed ID: 16299245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET.
    Zhou JY; Chen X; Zhao J; Bao Z; Chen X; Zhang P; Liu ZF; Zhou JY
    Cancer Lett; 2014 Sep; 351(2):265-71. PubMed ID: 24983493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway.
    Wu H; Fan F; Liu Z; Shen C; Wang A; Lu Y
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):307-15. PubMed ID: 26063323
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors.
    Bladt F; Faden B; Friese-Hamim M; Knuehl C; Wilm C; Fittschen C; Grädler U; Meyring M; Dorsch D; Jaehrling F; Pehl U; Stieber F; Schadt O; Blaukat A
    Clin Cancer Res; 2013 Jun; 19(11):2941-51. PubMed ID: 23553846
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer.
    Cascone T; Xu L; Lin HY; Liu W; Tran HT; Liu Y; Howells K; Haddad V; Hanrahan E; Nilsson MB; Cortez MA; Giri U; Kadara H; Saigal B; Park YY; Peng W; Lee JS; Ryan AJ; Jüergensmeier JM; Herbst RS; Wang J; Langley RR; Wistuba II; Lee JJ; Heymach JV
    Clin Cancer Res; 2017 Sep; 23(18):5489-5501. PubMed ID: 28559461
    [No Abstract]   [Full Text] [Related]  

  • 34. Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607.
    Dai Y; Siemann DW
    BMC Cancer; 2012 May; 12():198. PubMed ID: 22639908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of MET inhibition on small-cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway.
    Taniguchi H; Yamada T; Takeuchi S; Arai S; Fukuda K; Sakamoto S; Kawada M; Yamaguchi H; Mukae H; Yano S
    Cancer Sci; 2017 Jul; 108(7):1378-1385. PubMed ID: 28474864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.
    Baltschukat S; Engstler BS; Huang A; Hao HX; Tam A; Wang HQ; Liang J; DiMare MT; Bhang HC; Wang Y; Furet P; Sellers WR; Hofmann F; Schoepfer J; Tiedt R
    Clin Cancer Res; 2019 May; 25(10):3164-3175. PubMed ID: 30674502
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer.
    De Bacco F; Luraghi P; Medico E; Reato G; Girolami F; Perera T; Gabriele P; Comoglio PM; Boccaccio C
    J Natl Cancer Inst; 2011 Apr; 103(8):645-61. PubMed ID: 21464397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-Met /PI3k/Akt/mTOR pathway.
    Chen QY; Jiao DM; Wu YQ; Chen J; Wang J; Tang XL; Mou H; Hu HZ; Song J; Yan J; Wu LJ; Chen J; Wang Z
    Oncotarget; 2016 Apr; 7(14):18247-61. PubMed ID: 26919096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanisms of hepatocyte growth factor-induced retinal endothelial cell migration and growth.
    Cai W; Rook SL; Jiang ZY; Takahara N; Aiello LP
    Invest Ophthalmol Vis Sci; 2000 Jun; 41(7):1885-93. PubMed ID: 10845613
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts.
    Puri N; Khramtsov A; Ahmed S; Nallasura V; Hetzel JT; Jagadeeswaran R; Karczmar G; Salgia R
    Cancer Res; 2007 Apr; 67(8):3529-34. PubMed ID: 17440059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.